Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways
出版年份 2018 全文链接
标题
Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways
作者
关键词
Bladder cancer, Urothelial cancer, Immunotherapy, Immune checkpoint inhibitors, PD-1, PD-L1, CTLA-4
出版物
WORLD JOURNAL OF UROLOGY
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-06-01
DOI
10.1007/s00345-018-2332-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
- (2017) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Novel therapeutic targets in advanced urothelial carcinoma
- (2016) Mathieu Rouanne et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Recommandations en onco-urologie 2016-2018 du CCAFU : Tumeurs de la vessie
- (2016) M. Rouprêt et al. PROGRES EN UROLOGIE
- Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
- (2014) J. Bellmunt et al. ANNALS OF ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
- (2014) C. Tang et al. Cancer Immunology Research
- Second-line systemic therapy for metastatic urothelial carcinoma of the bladder
- (2013) Christina Ann Ortmann et al. Future Oncology
- Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
- (2013) Silvia C. Formenti et al. JNCI-Journal of the National Cancer Institute
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
- Inflammatory cytokines as a third signal for T cell activation
- (2010) Julie M Curtsinger et al. CURRENT OPINION IN IMMUNOLOGY
- Combination approaches to immunotherapy: the radiotherapy example
- (2009) Michael J Gough et al. Immunotherapy
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started